Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Operating Leases (2019 - 2025)

Autolus Therapeutics (AUTL) has disclosed Operating Leases for 6 consecutive years, with $65.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 35.29% year-over-year to $65.8 million, compared with a TTM value of $65.8 million through Sep 2025, up 35.29%, and an annual FY2024 reading of $49.6 million, down 6.3% over the prior year.
  • Operating Leases was $65.8 million for Q3 2025 at Autolus Therapeutics, up from $61.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $65.8 million in Q3 2025 and bottomed at $11.3 million in Q3 2022.
  • Average Operating Leases over 4 years is $42.1 million, with a median of $48.7 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 315.27% in 2023, then fell 6.3% in 2024.
  • Year by year, Operating Leases stood at $19.2 million in 2022, then skyrocketed by 175.61% to $53.0 million in 2023, then decreased by 6.3% to $49.6 million in 2024, then skyrocketed by 32.65% to $65.8 million in 2025.
  • Business Quant data shows Operating Leases for AUTL at $65.8 million in Q3 2025, $61.3 million in Q2 2025, and $57.7 million in Q1 2025.